Journal of Vascular Medicine & Surgery

ISSN: 2329-6925

Journal of Vascular Medicine & Surgery
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business

Lymphangiogenesis and its Role in Physiologic Wound Healing and the Pathogenesis of Pulmonary Fibrosis

Sarah MH and Abigail L*
Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado at Denver, University of Colorado, Aurora, USA
Corresponding Author : Abigail L
Division of Pulmonary Sciences and Critical Care Medicine
University of Colorado at Denver
University of Colorado
Aurora, USA
Tel:
303-724-6167
E-mail:
Abigail.Lara@UCDenver.edu
Received June 25, 2015; Accepted November 23, 2015; Published December 10, 2015
Citation: Sarah MH, Abigail L (2015) Lymphangiogenesis and its Role in Physiologic Wound Healing and the Pathogenesis of Pulmonary Fibrosis. J Vasc Med Surg 3:236. doi:10.4172/2329-6925.1000236
Copyright: © 2015 Sarah MH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google
Visit for more related articles at Journal of Vascular Medicine & Surgery
 

Abstract

Wound healing and repair is a physiologic process that occurs following tissue injury often resulting in a controlled scar formation. However, in certain disease states, the intrinsic mechanisms that signal the completion of repair are defunct leading to continued repair, resulting in excessive fibrosis. Numerous segments of the wound healing process are known to be deregulated in idiopathic pulmonary fibrosis (IPF) including increased myofibroblast activation, excessive extracellular matrix (ECM) deposition, and decreased injury resolution. In this review we will focus on one part of the wound healing process, lymphangiogenesis and lymphatic remodeling, and its potential role in the pathogenesis of pulmonary fibrosis.

Keywords
Lymphangiogenesis; Lymphatic vessels; Idiopathic pulmonary fibrosis
Introduction
Wound healing and repair is a physiologic process that occurs following tissue injury often resulting in a controlled scar formation. However, in certain disease states, the intrinsic mechanisms that signal the completion of repair are defunct leading to continued repair, resulting in excessive fibrosis. Numerous segments of the wound healing process are known to be deregulated in idiopathic pulmonary fibrosis (IPF) including increased myofibroblast activation, excessive extracellular matrix (ECM) deposition, and decreased injury resolution [1]. In this review we will focus on one part of the wound healing process, lymphangiogenesis and lymphatic remodeling, and its potential role in the pathogenesis of pulmonary fibrosis.
Normal Wound Healing and Repair
In response to tissue injury, the wound healing process follows three tightly regulated phases: (1) injury, (2) inflammation, and (3) repair, with the goal to re-establish tissue homeostasis [1]. In the first phase following injury, damage to the endothelium results in activation of the clotting cascade, platelet activation, and the formation of a fibrin clot that is critical step for the second phase of wound healing by acting as a scaffold for infiltrating inflammatory cells and fibroblasts to accumulate at the site of injury [2].
The second phase of wound repair is marked by release of a milieu of cytokines, chemokines, and growth factors that are secreted by both resident cells and infiltrating inflammatory cells and fibroblasts. These soluble factors promote myofibroblast activation to produce collagen, direct changes in inflammatory cell phenotype, stimulate angiogenesis, and lymphangiogenesis. Vascular endothelial growth factor A (VEGF-A) and fibroblast growth factor 2 (FGF-2) are proangiogenic factors that are released in response to injury and initiate the growth of new blood vessels to transport nutrients and infiltrating cells to the site of injury [2]. After a temporal delay, lymphangiogenesis occurs in order to facilitate inflammatory cell trafficking to and from the site of injury. In a mouse model of chronic airway inflammation, capillary enlargement occurred by day 7 following inoculation with Mycoplasma Pulmonis, whereas lymphatic remodeling occurred later with lymphatic sprouting beginning on day 14 [3]. Taken together, the expansion of both blood and lymphatic vessels that occurs during the inflammatory phase of wound repair helps to regulate the influx and phenotype of infiltrating cells in the wound through cytokine, chemokine, and growth factor signaling to ultimately facilitate reepithelialization and wound closure.
In the final phase, inflammatory cytokines and growth factors are no longer produced and the infiltrating cells undergo apoptosis. In addition, the collagen produced by the myofibroblasts undergoes remodeling from type III to type I collagen to increase scar stability [1,2]. In IPF, there is evidence of increased type 2 inflammatory cytokine profile (IL-4, IL-13, and TGFβ1), angiogenesis, myofibroblast activation, and importantly Lymphangiogenesis [1].
Molecular Mechanisms of Lymphangiogenesis
Lymphatic vessels are present throughout the human body, serving as conduits for immune cell trafficking and interstitial fluid balance. Similar to the blood vasculature, new lymphatic vessels in adults are thought to arise from pre-existing lymphatics and bone marrow derived lymphatic endothelial precursor cells [4-6].
The VEGF family of receptors and ligands are important in the regulation of growth and survival of both blood and lymphatic vessels. During inflammation, leukocytes and macrophages secrete VEGFC/ D that bind to VEGFR-3 and VEGFR-2 expressed on the surface of LECs to promote Lymphangiogenesis [4,7,8]. Binding of VEGF-C to VEGFR-3 signals Akt phosphorylation and activation of p42/p44 mitogen-activated protein kinase [MAPK] resulting in LEC survival and migration [9]. Increased VEGF signaling regulates lymphatic growth and survival, whereas reduced VEGF signaling results in lymphatic regression [4]. Abnormal lymphatic growth is known to occur in many fibrotic diseases, including renal tubulointerstitial fibrosis and the alloimmune response to cardiac transplant [10,11]. Although lymphangiogenesis has been reported in many fibrotic diseases, the role that the remodeled lymphatic vasculature plays in the progression of fibrosis and the molecular mechanisms that drive this not well understood. It is possible that the soluble factors that are secreted by LECs during lymphangiogenesis influence both resident and circulating cells. CCL21, a cytokine known to be secreted by LECs that binds CCR7 present on activated dendritic cells, T and B cells, is being investigated as a promising soluble factor secreted by LECs to attract and alter the phenotype of circulating CCR7 positive cells [12,13].
Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis affects 50 in 100,000 people and is a progressive fibrotic disease of the lung characterized by areas of fibroblastic foci and increased ECM deposition [14]. The pathogenesis of IPF is unknown, but is thought to involve an unknown trigger in the setting of a predisposed lung in addition to repeated micro-injury and aberrant wound repair [1,15]. What triggers the fibroblast to transform into activated myofibroblasts resulting in ECM deposition and progressive scar formation is not completely understood. Additionally, little is known about early events following the initial injury before the lung has become laden with excessive ECM. Recent evidence suggests that lymphangiogenesis may occur early after lung injury, facilitating inflammatory cell and fibroblast cell trafficking to areas of early fibrosis, and additionally may play a role in altering the phenotype of the infiltrating cells [16,17].
The Role of Lymphatic Remodeling in Idiopathic Pulmonary Fibrosis
An expanded network of lymphatic vessels has been observed in Idiopathic Pulmonary Fibrosis (IPF) and has been implicated in the pathogenesis of pulmonary fibrosis. Morphometric abnormalities including increased lymphatic vessel length density, lymphatic vessel area can be found in IPF when compared to normal lung [16,17]. These morphometric changes correlate with degree of histopathologic fibrosis and clinical severity of disease. In addition to increased lymphangiogenesis, lymphatic vessels in IPF, in comparison to normal lung, are distributed in different areas throughout the lung. In the normal lung, most lymphatic vessels are present along large blood vessels and airways with little lymphatic vessels distant from blood vessels or airways [18]. Although it is clear that lymphangiogenesis and remodeling of the lymphatic vasculature in present in the IPF lung, there is ongoing debate regarding if lymphangiogenesis occurs de novo or is an expansion of preexisting lymphatic vessels.
Macrophages have been shown to trans-differentiate into LEC-like cells that form tubes in culture under conditions that simulate a fibrotic lung, suggesting that macrophages in IPF trans-differentiate into LECs forming the modified lymphatic vasculature [16]. Conversely, lymphatic proliferation can occur from preexisting lymphatics in response to VEGF-C/D signaling through VEGFR-3. In contrast to normal wound healing where lymphatic vessels regress as the wound is repaired, the lymphatic vessels in IPF do not appear to regress. Whether there is an absence of signaling instructing the vessels to regress or there is a persistence of pro-growth signaling is unclear. How this expanded network of lymphatic vessels contributes to the pathogenesis of IPF is unknown.
Lymphangiogenesis may contribute to the pathogenesis by attracting circulating inflammatory cells and fibrocytes; alternatively, the persistence of lymphatic vessel growth may attenuate the degree of fibrosis that might otherwise occur by draining inflammatory cells and fibroblasts from the lung. IPF cultured fibroblasts are reported to express CCR7 and show both migratory and proliferative response when exposed to CCL21 [19]. Furthermore, CCL21 is increased in the bronchoalveolar lavage fluid (BALF) from IPF patients suggesting the lymphatic vasculature in IPF may promote the progression of fibrosis [16]. Whether CCL21-CCR7 signaling can affect the phenotype of infiltrating fibrocytes has not been elucidated.
Conclusion
IPF is a progressive fibrotic lung disease that may partially arise from aberrant wound repair. Increased lymphangiogenesis and lymphatic remodeling is present in IPF and may contribute to disease progression by producing cytokines and growth factors that attract cells to areas of progressive fibrosis and alter the phenotype of infiltrating cells. CCL21- CCR7 signaling appears to be involved in fibrocyte trafficking to areas of progressing fibrosis. The stimulus of lymphangiogenesis in the IPF lung may remain as elusive as the trigger for fibrosis, however further insights into their role in the pathogenesis of IPF should be explored as elucidation of their role may offer novel therapeutic targets for this devastating disease.
References






































Select your language of interest to view the total content in your interested language
Post your comment
Share This Article
   
 
   
 
Relevant Topics
Disc Abdominal Aortic Aneurysm
Disc Arteries
Disc Arteriosclerosis
Disc Blood Clot Symptoms
Disc Brain Aneurysm Symptoms
Disc Cardiac Arrest
Disc Cardiac Cachexia
Disc Cardiac Dysrhythmias
Disc Cardiopulmonary Resuscitation
Disc Cardiovascular Drugs
Disc Cardiovascular Drugs Market Analysis
Disc Cardiovascular Medicine
Disc Cardiovascular Pharmacotherapy
Disc Cardiovascular Physiology
Disc Cardiovascular Safety Pharmacology
Disc Cardiovascular Toxicology
Disc Carotid Artery
Disc Cineangiography
Disc Congestive Heart Failure
Disc Coronary Heart Disease
Disc Cyanotic Heart Disease
Disc Emerging Infectious Diseases
Disc Endocrine Surgery
Disc Epidemiology
Disc Femoral Artery
Disc Gastrointestinal drugs and market analysis
Disc Gynecologic Surgery
Disc Heart Disease
Disc Hip surgery
Disc Hydrocele surgery
Disc Hypotension
Disc Ischemic Heart Disease
Disc Laparoscopic Surgery
Disc Laparotomy surgery
Disc Laser Surgery
Disc Liver Resection Surgery
Disc Liver surgery
Disc Liver transplant surgery
Disc Minimally invasive surgery
Disc Myocardial Infarction
Disc Neck surgery
Disc Neglected Tropical Diseases
Disc Neonatal Surgery
Disc Noncommunicable Diseases
Disc Oculoplastic surgery
Disc Oncologic Surgery
Disc Outpatient surgery
Disc Peripheral Vascular Disease
Disc Plantal fasciitis surgery
Disc Rheumatic Heart Disease
Disc Robotic Surgery
Disc Sciaticia surgery
Disc Stent
Disc Surgical oncology
Disc Thoracic surgery
Disc Toe surgery
Disc Transplant Surgery
Disc Trauma Surgery
Disc Tropical Biomedicine
Disc Tropical Diseases
Disc Tropical Fish Diseases
Disc Tropical Fish Medicine
Disc Tropical Health Nutrition
Disc Tropical Medicine
Disc Tropical Medicine Case Reports
Disc Tropical Medicine Research
Disc Tropical Medicine and Health
Disc Tropical Medicine and Hygiene
Disc Tropical Medicine and Infectious Diseases
Disc Tropical Medicine and Parasitology
Disc Tropical Veterinary Medicine
Disc Varicose surgery
Disc Vascular
Disc Vascular Dementia
Disc Vector Borne Diseases
Disc Vitreoretinal Surgery
 
Recommended Journals
Disc Cardiovascular Research Journal
Disc Endovascular Surgery Journal
Disc Cardiology Journal
Disc Pharmacology Journal
Disc Surgery Journal
Disc Tropical Medicine Journal
Disc Current Research in Surgery Journal
Disc Cardiovascular Pharmacology Journal
  View More»
 
Recommended Conferences
Disc Medical-Surgical Nursing
Oct 10-12, 2016, Kuala Lumpur, Malaysia
Disc World Congress On Vascular Diseases, Medicine & Surgeons Summit
October 24-25, 2016 Chicago, Illinois, USA
Disc Cardiology Congress
Oct 17-19, 2016 Rome, Italy
Disc Nursing and Healthcare
Dec 05-07, 2016, Dallas, USA
View More»
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 7608
  [From(publication date):
December-2015 - Sep 25, 2016]
  Breakdown by view type
  HTML page views : 7545
  PDF downloads :63
 
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version